Pharmala Biotech Holdings Inc. (CSE:MDMA)
0.2300
-0.0100 (-4.17%)
Aug 28, 2026, 3:39 PM EST
Pharmala Biotech Holdings Revenue
Pharmala Biotech Holdings had revenue of 513.23K CAD in the quarter ending May 31, 2026, with 279.70% growth. This brings the company's revenue in the last twelve months to 1.27M, up 201.24% year-over-year. In the fiscal year ending August 31, 2025, Pharmala Biotech Holdings had annual revenue of 605.50K, down -41.51%.
Revenue (ttm)
1.27M
Revenue Growth
+201.24%
P/S Ratio
19.82
Revenue / Employee
n/a
Employees
n/a
Market Cap
25.12M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 605.50K | -429.80K | -41.51% |
| Aug 31, 2024 | 1.04M | 503.29K | 94.60% |
| Aug 31, 2023 | 532.00K | 453.93K | 581.44% |
| Aug 31, 2022 | 78.07K | - | - |
| Aug 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Telescope Innovations | 7.30M |
| Devonian Health Group | 3.00M |
| Rapid Dose Therapeutics | 2.58M |
| Onco-Innovations | 110.38K |
| The More Life Company | 65.00K |
Pharmala Biotech Holdings News
- 3 days ago - Water Tower Research Publishes Initiation of Coverage Report on PharmAla Biotech Holdings, Inc., "Monetizing Regulatory Advantage Through IP and Data" - TheNewswire
- 9 days ago - PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner - GlobeNewsWire
- 4 weeks ago - PharmAla reports Q3 revenue C$513,000 vs. C$135,000 last year - TheFly
- 4 weeks ago - PharmAla Issues Q3 Financial Statements and AGM Update - GlobeNewsWire
- 4 weeks ago - Pharmala Biotech Holdings Registration statement: Q3 2026 - Filings
- 4 weeks ago - Pharmala Biotech Holdings Registration statement: Q3 2026 - Filings
- 4 weeks ago - Pharmala Biotech Holdings Earnings release: Q3 2026 - Filings
- 5 weeks ago - PharmAla enters up to $100M ALA-002 license pact with Jupiter Neurosciences - TheFly